Aeglea BioTherapeutics
Drugs for the treatment of tumors the company was incorporated in 2013 and is based in texas.
Launch date
Employees
Market cap
€1.4b
Enterprise valuation
€1.0b (Public information from Sep 2024)
Share price
$30.4 AGLE
Austin Texas (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 18.7m | 2.3m | <1m | 3.3m | 5.0m | <1m |
| % growth | - | - | (88 %) | (62 %) | 276 % | 50 % | (95 %) |
| EBITDA | (80.5m) | (65.6m) | (84.8m) | (242m) | (170m) | (178m) | - |
| % EBITDA margin | - | (350 %) | (3640 %) | (27269 %) | (5098 %) | (3560 %) | - |
| Profit | (80.9m) | (65.8m) | (83.8m) | (339m) | (169m) | (194m) | (235m) |
| % profit margin | - | (351 %) | (3599 %) | (38239 %) | (5065 %) | (3884 %) | (93920 %) |
| EV / revenue | - | 12.5x | 11.9x | 491.6x | 330.9x | 179.8x | 5840.0x |
| EV / EBITDA | -4.7x | -3.6x | -0.3x | -1.8x | -6.5x | -5.0x | - |
| R&D budget | 59.6m | 57.1m | 58.6m | - | - | - | - |
| R&D % of revenue | - | 305 % | 2515 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$12.0m | Series A | ||
$44.0m | Series B | ||
| N/A | N/A | IPO | |
* | $210m | Post IPO Convertible | |
| Total Funding | €50.9m | ||
Related Content
Recent News about Aeglea BioTherapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Aeglea BioTherapeutics
Edit
ACQUISITION by Aeglea BioTherapeutics Jun 2023